Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0KB0Y
|
|||
| Drug Name |
Pegargiminase
|
|||
| Synonyms |
ADI-PEG-20
Click to Show/Hide
|
|||
| Drug Type |
Recombinant protein
|
|||
| Indication | Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 3 | [1] | |
| Mesothelioma [ICD-11: 2C51.2; ICD-10: C45; ICD-9: 163] | Phase 2/3 | [2], [3] | ||
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2 | [3] | ||
| Gastrointestinal cancer [ICD-11: 2C11] | Phase 1/2 | [2] | ||
| Argininosuccinate synthase deficiency [ICD-11: 5C50.A3] | Phase 1 | [2] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [2] | ||
| Company |
Polaris Pharmaceuticals
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Polaris Pharmaceuticals. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.